Replies to post #202096 on Cytodyn Inc (CYDY)

[crazyjogger925]

statement by nader re nash:

"Hitting our primary endpoint in both ITT and per protocol (PP) and secondary endpoint in PP with such short trial (14-week trial as compared to usually 24 to 32-week NASH trials) is a very strong statement of leronlimab’s potential. We believe we have a unique drug with tremendous opportunities.”

[Buddyboy20]

More information from Ohm20:

"NAFLD is where NASH starts but it doesn't necessarily progress to NASH. The difference between NAFLD and NASH is the level of fibrosis. In NAFLD fibrosis may just be starting to occur. If fibrosis continues hen you end up in one of the four levels of NASH.

The proper way to do it is to look at NASH vs. NASH which I outlined here -

I've previously said the 350mg results were good but not great but even those results seem to be more than a match for Madrigal. The problem for comparison is incomplete data from both companies.

The matchup is from Cytodyn's 14 week trial vs. Madrigal's 52 week data. Longer usage of leronlimab should skew the data better for leronlimab especially in MRI-PDFF.

Knowing that leronlimab has always shown better effect at the higher dose it would not surprise me to see a 10% to 15% better result from 700mg than from 350mg."

[HyGro]

Read the 10Q report 1/10/22. The

1. "Our cash reserves are extremely low, requiring that we raise substantial additional financing to satisfy our current payment obligations and to fund our operations." About $8 mil in cash 11/30/21. Have raised ~$13 mil since then. Have S-3 for a secondary so can't sell more stock. Vulture fund won't give them anymore cash -- cashing out the maximum each month to get their money back. Paulson private placement was a disaster for private investors -- they lost over 50% in just over a month. No more money there. So virtually no ability to raise cash. Will be out of cash in February.

2. "We have received notice of a material breach of our payment obligations to Samsung, which could result in termination of our agreements for manufacturing of our drug product and related services by Samsung." Can't pay the $35 mil to Samsung plus the $50 mil to vulture fund -- total of more ~$100 mil in debt they can't pay.

3. "We are required to post a $6.5 million bond in the dispute with our former contract research organization, which requires us to provide cash collateral to secure the full amount of the bond." Don't even have the cash to put up the $6.5 mil surety bond to get their clinical trial data back -- so no BLA.

So, out of cash February and can't raise more, can't pay $100 mil in mostly past due debt -- that's bankruptcy.